Loading…
← CockpitCompetitor Analysis › GPCR Structure Therapeutics, Inc. Sponsored ADROpen in the cockpit ↗

Structure Therapeutics, Inc. Sponsored ADRGPCRCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage biotech developing oral small-molecule GLP-1 drugs for obesity and metabolic disease.

Momentum laggard 5
Mkt cap
$1.24B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$19.3M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$17.36
1D-4.5%
1W-17.1%
1M-24.1%
3M-65.6%
6M-52.9%
YTD-75.0%
1Y-53.6%
ATR %8.4%
Beta1.20
52w lowhigh81.7% off high

What Structure Therapeutics, Inc. Sponsored ADR does

Clinical-stage biotech developing oral small-molecule GLP-1 drugs for obesity and metabolic disease.

Has no approved product and no partner revenue, so it is funded by selling shares to investors. Its research is split between South San Francisco and Shanghai. The case for its drug is a daily pill that avoids the injections used by most weight-loss drugs today.

Products and services

  • GSBR-1290 (oral GLP-1 agonist)
  • Pipeline GPCR programs

Where it sits in the supply chain

  • Biopharma R&D
  • GPCR-targeted small-molecule discovery
  • Oral GLP-1 clinical development

What could go right

  • Positive oral GLP-1 data vs Lilly/Novo
  • Partnership/licensing deal

What could go wrong

  • Intensely competitive, well-capitalized rivals
  • Binary trial-data risk

Moat: none (IP / patents). Pre-commercial; competing against well-funded incumbents in the crowded oral GLP-1 obesity race.

Headquarters: South San Francisco, California, US · Founded: 2019 · Employees: 220

Named competitors

Structure Therapeutics, Inc. Sponsored ADR at a glance

Size Structure Therapeutics, Inc. Sponsored ADR (GPCR) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.24B, the 2097th largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.36 on 18 Nov 2026.

Performance Over six months the shares fell 52.9%, against -20.6% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Short interest Short interest is 8.3% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

5010015021 May 202621 Aug 202618 Nov 2026Peer median 81GPCR 45
Six months, rebased to 100: Structure Therapeutics, Inc. Sponsored ADR against the median of its 20 peers (local-currency closes).

Structure Therapeutics, Inc. Sponsored ADR financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$4.74M-$3.90M-$2.60M-$949,174-$623,259
EBITDA-$447M-$284M-$156M-$102M-$51.9M
Net income-$295M-$142M-$123M-$89.5M-$51.3M
Free cash flow-$278M-$226M-$118M-$81.6M-$46.2M
Capital expenditure$6.30M$3.62M$1.29M$2.17M$154,816
Total debt$6.83M$6.49M$3.86M$5.45M$260,001

Quarterly statements and history in the cockpit →

Structure Therapeutics, Inc. Sponsored ADR competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%000950AVLN688076300026IDIA300204347850AMPHHROW26163000060023322493301263LBRX6883216884436855GPCR6-month return →1-month return →
Up and to the right = strong over both horizons. Structure Therapeutics, Inc. Sponsored ADR is the large dot.

Structure Therapeutics, Inc. Sponsored ADR competitors and peer comparison

Head to head with its named competitors (GPCR vs LLY vs NOVO-B.CO vs VKTX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Structure Therapeutics, Inc. Sponsored ADR GPCR$1.24B-53%n/an/an/an/a
Lilly (Eli) LLY$1.30T+36%+46%51%15.6×6.5%
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%3.9×-0.5%
Viking Therapeutics VKTX$3.34B-9%n/an/an/an/a
Pfizer PFE$160B+9%+1%26%3.3×-4.3%

How Structure Therapeutics, Inc. Sponsored ADR compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Structure Therapeutics, Inc. Sponsored ADR against its 20 peers (data as of 18 Nov 2026)
MeasureGPCRPeer medianRank in peer set
1-month return-24.1%-5.1%lowest of 21
6-month return-52.9%-20.6%lowest of 21
Distance from 52-week high-81.7%-41.7%lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%0.5×n/an/a
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%4.8×3.4%+27.9%
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%1.8×7.0%-5.3%
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%10.4×n/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%39.1×n/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%818.8×n/an/a
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%2.3×2.5%+15.5%
Harrow HROWUnited States$1.21B+4%+21%1%4.7×n/an/a
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%17.0×n/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%10.4×44.1%-13.2%
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%2.0×-0.4%-1.3%
Mabwell (Shanghai) Bioscience 2493.HKHong Kong$1.20B-29%+21%-127%13.6×n/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%12.8×n/an/a
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%7.6×n/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%8.6×n/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%13.3×n/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%13.2×n/an/a

Questions

Who are Structure Therapeutics, Inc. Sponsored ADR's main competitors?
Named competitors: Eli Lilly (orforglipron) (LLY), Novo Nordisk (NOVO-B.CO), Viking Therapeutics (VKTX), Pfizer (PFE). The cockpit's measured peer set (industry) also includes C.Q. Pharmaceutical (000950.SZ), Avalyn Pharma (AVLN), Sinopep-Allsino Bio Pharmaceutical (688076.SS), Tianjin Chase Sun Pharmaceutical (300026.SZ), GH Research (GHRS), Idorsia (IDIA.SW).
How has Structure Therapeutics, Inc. Sponsored ADR stock performed?
Over six months to 18 Nov 2026 the shares returned -52.9% against -20.6% for the median peer; over one year -53.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.